PILOCARPINE SUMMARY
Pilocarpine Hydrochloride Tablets
Pilocarpine Hydrochloride Tablets contain pilocarpine hydrochloride, a cholinergic agonist for oral use. Pilocarpine hydrochloride is a hygroscopic, odorless, bitter tasting white crystal or powder, which is soluble in water and alcohol and virtually insoluble in most non-polar solvents.
Pilocarpine Hydrochloride Tablets are indicated for the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck.
|
NEWS HIGHLIGHTS
Published Studies Related to Pilocarpine
Comparison of the effects of pilocarpine and cevimeline on salivary flow. [2009.05]
OBJECTIVE: The aim of the present study was to compare the effect of low-dose pilocarpine and cevimeline as stimulants for salivary flow in healthy subjects... CONCLUSION: Both drugs showed efficacy in increasing the salivary flow in healthy volunteers, but cevimeline was more effective than pilocarpine.
Reducing the incidence of 131I-induced sialadenitis: the role of pilocarpine. [2008.04]
The goal of this study was to reduce the salivary symptoms of pain and xerostomia caused by 131I therapy for papillary and follicular thyroid carcinoma... CONCLUSION: Under the conditions of the study, pilocarpine did not reduce the occurrence of radiation sialadenitis or stomatitis. The occurrence, however, was lower than had previously been reported in the literature, possibly because of the concurrent stringent application of physiologic sialogogues (candy, gum, fluids), dexamethasone, and dolasetron mesylate, a serotonin receptor antagonist.
Protection of salivary function by concomitant pilocarpine during radiotherapy: a double-blind, randomized, placebo-controlled study. [2008.01.01]
CONCLUSIONS: Concomitant administration of pilocarpine during radiotherapy did not improve the PFCP or LENT SOMA and patient-rated xerostomia scores. In a subgroup of patients with a mean dose above 40 Gy, pilocarpine administration resulted in sparing of parotid gland function. Therefore, pilocarpine could be provided to patients in whom sufficient sparing of the parotid is not achievable.
Protection of Salivary Function by Concomitant Pilocarpine During Radiotherapy: A Double-Blind, Randomized, Placebo-Controlled Study. [2007.09.13]
CONCLUSIONS: Concomitant administration of pilocarpine during radiotherapy did not improve the PFCP or LENT SOMA and patient-rated xerostomia scores. In a subgroup of patients with a mean dose above 40 Gy, pilocarpine administration resulted in sparing of parotid gland function. Therefore, pilocarpine could be provided to patients in whom sufficient sparing of the parotid is not achievable.
Pilocarpine hydrochloride for the treatment of xerostomia in patients with Sjogren's syndrome in Taiwan--a double-blind, placebo-controlled trial. [2006.10]
BACKGROUND/PURPOSE: Sjogren's syndrome (SS) is characterized by diminished exocrine secretions with the resultant symptoms of dry mouth and dry eye. As genetic predisposition and ethnicity may alter the effectiveness of drug treatment, evaluation of the efficacy and safety of the secretagogue pilocarpine hydrochloride in the treatment of xerostomia in patients with SS in different populations is needed... CONCLUSION: The results of this study suggest that therapy with 5 mg pilocarpine four times daily is effective, safe and well tolerated for the relief of oral symptoms in patients with SS in Taiwan.
Clinical Trials Related to Pilocarpine
A Comparison of Orally Pilocarpine and Artificial Saliva in Xerostomy Treatment [Completed]
Pilocarpine in Treating Patients With Dry Mouth Caused by Opioids [Active, not recruiting]
RATIONALE: Pilocarpine may help to relieve dry mouth in patients receiving opioids for cancer
therapy. It is not yet known whether pilocarpine is more effective than no further treatment
for this condition.
PURPOSE: Randomized phase III trial to determine the effectiveness of pilocarpine in treating
patients who have dry mouth caused by opioids.
Bioequivalency Study of 5 mg Pilocarpine Tablets Under Fasting Conditions [Completed]
The objective of this study was the bioequivalence of a Roxane Laboratories' Pilocarpine
Tablets, 5 mg, to SALAGEN® Tablets, 5 mg (MGI Pharma) under fasting conditions using a
single-dose, 2-treatment, 2-period, crossover design.
Bioequivalency Study of 7.5 mg Pilocarpine Under Fed Conditions [Completed]
The objective of this study was the bioequivalence of a Roxane Laboratories' Pilocarpine
tablets, 7. 5 mg, to SALAGEN® Tablets, 7. 5 mg (MGI) under fed conditions using a single-dose,
randomized, 2-treatment, 2-period, 2-sequence crossover design.
Bioequivalency Study of 7.5 mg Pilocarpine Tablets Under Fasting Conditions [Completed]
The objective of this study was the bioequivalence of a Roxane Laboratories' Pilocarpine
tablets, 7. 5 mg, to SALAGEN® Tablets, 7. 5 mg (MGI) under fasting conditions using a
single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design.
|
|
|
|
Page last updated: 2009-10-20
|
